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Depression is an important target of psychological
assessment in patients with end-stage renal disease because
it predicts their morbidity, mortality, and quality of life. We
assessed the effectiveness of cognitive–behavioral therapy
in chronic hemodialysis patients diagnosed with major
depression by the Mini International Neuropsychiatric
Interview (MINI). In a randomized trial conducted in Brazil,
an intervention group of 41 patients was given 12 weekly
sessions of cognitive–behavioral group therapy led by a
trained psychologist over 3 months while a control group
of 44 patients received the usual treatment offered in the
dialysis unit. In both groups, the Beck Depression Inventory,
the MINI, and the Kidney Disease and Quality of Life-Short
Form questionnaires were administered at baseline, after
3 months of intervention or usual treatment, and after
9 months of follow-up. The intervention group had significant
improvements, compared to the control group, in the
average scores of the Beck Depression Inventory overall
scale, MINI scores, and in quality-of-life dimensions that
included the burden of renal disease, sleep, quality of
social interaction, overall health, and the mental component
summary. We conclude that cognitive–behavioral group
therapy is an effective treatment of depression in chronic
hemodialysis patients.
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Depression is the most important target of psychological
assessment in patients with end-stage renal disease (ESRD),1
because it has been proven to be an important predictor of
morbidity, mortality, and quality of life in these patients.2–8 It
is associated with immunological changes such as decreased
cellular immunity and increased cytokine levels,9,10 with
inflammatory processes indicated by interleukin-6 activity,11
with an increased likelihood of hospitalizations,4 and with
the development of peritonitis in those receiving peritoneal
dialysis.5 The symptoms of depression are also a risk factor
for the decision to discontinue dialysis12 and may signifi-
cantly impair interdialytic weight control.13 Depression is a
persistent problem in these patients, and it does not tend to
improve over time.14,15
Cognitive–behavioral therapy (CBT) is the most investi-
gated psychological treatment in the literature,16 as it has
been found to be effective in decreasing the symptoms and
recurrences of psychological diseases.17 Since the 1990s, CBT
has been suggested to be an important option for improving
the survival of patients on hemodialysis;18 however, there are
very few studies on the psychological treatment of depression
in these patients. Most published studies have very small
samples or inadequate methodology.19–21 The need for
randomized clinical trials for the treatment of depression in
patients with ESRD has been emphasized.14,22–24
The objective of this study was to assess the effectiveness
of an intervention with CBT in ESRD patients with a
diagnosis of major depression.
RESULTS
Of all the patients undergoing hemodialysis in the two units
and who were initially available to participate in the study
(n¼ 350), 12 declined to participate and 238 did not meet
the inclusion criteria (age 480 years (n¼ 17), unable to
understand the study protocol or questionnaires (n¼ 6),
scheduled for living donor transplantation (n¼ 4), hospita-
lized (n¼ 3), psychotic symptoms (n¼ 2), anxiety disorder
(n¼ 2), undergoing chemotherapy for cancer (n¼ 2), bed-
ridden (n¼ 2), alcoholism (n¼ 1), and anti-social person-
ality disorder (n¼ 1), and, of the remaining patients, 198 did
not have a diagnosis of major depression). The mean Beck
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Depression Inventory (BDI) score for the excluded popula-
tion (n¼ 198) was 7.8±4.4. Therefore, 100 patients with a
diagnosis of depression were eligible for the study. However,
10 patients were lost before enrollment in the study because
of consent withdrawal (n¼ 5), death (n¼ 3), hospitalization
(n¼ 1), and exclusion due to psychotic symptoms (n¼ 1).
Therefore, 90 patients were randomized, with 46 allocated to
the intervention group and 44 to the control group. During
the first 3 months, five patients were lost in the intervention
group because of consent withdrawal (n¼ 2), transplantation
(n¼ 2), and exclusion due to psychotic symptoms (n¼ 1).
None of the patients in the intervention group were
discontinued because of a CBT adverse effect. Thus, 85
patients were reevaluated after 3 months (41 in the
intervention group and 44 in the control group). Regarding
depression symptoms, there were 13 (31.7%) patients with
mild, 14 (34.1%) with moderate, and 14 (34.1%) with severe
symptoms in the intervention group; in the control group,
the corresponding figures were 6 (13.6%), 21 (47.7%), and 17
(38.6%), respectively (P not significant). Sixty-five percent
(n¼ 55) of the patients had a prior depression episode (26
(63%) in the intervention group and 29 (66%) in the control
group) and nine patients were receiving antidepressive drugs,
four in the intervention group and five in the control group
(Figure 1).
Compliance with CBT and control treatment
The mean participation in CBT sessions was 78.5%. Two
patients did not comply (less than 70% of the sessions) and
withdrew consent to participate. Compliance with the
homework requested during the program was 87.8%. In the
control group, the mean participation in the weekly sessions
during the first 3 months of the study was 85%. In this group,
the average number of psychological sessions during the 6
months of the maintenance phase was 1.2 per patient per
month.
The groups were homogeneous to most socio-demo-
graphic, clinical, and laboratory data (Table 1). However, the
intervention group had a lower percentage of married
patients, of those dwelling with family members, and of
individuals with cerebrovascular disease.
Primary outcomes
Compared with the control group, the intervention group
had a lower mean in the BDI cognitive subscale throughout
the assessment (Po0.001). Compared with the baseline
value, there was a significant reduction of the mean values in
this scale in the group receiving intervention after 3 and 9
months (Table 2). There was also a significant decrease in the
baseline value of the BDI somatic subscale after 3 months
(mean difference: 3.6±0.6 points, Po0.001) and after 9
months (mean difference: 4.5±0.8 points, Po0.001) of
intervention (Table 2). Similarly, there was a reduction in the
overall BDI mean scores after 3 months (mean difference:
10.1±1.7 points, Po0.001) and after 9 months (mean
difference: 13.4±2.0 points, Po0.001) (Table 2, Figure 2).
Even though a decrease was also observed in the BDI
subscales and in the total score in the control group, these
changes were substantially lower.
In the intervention group, there was a significant decrease
in the mean value of the Major Depression module (Mini
International Neuropsychiatric Interview (MINI)) after 3
months (mean±s.e. difference: 4.5±0.4 points, Po0.001)
and after 9 months (mean difference: 4.4±0.5 points,
Po0.001) of the baseline assessment. After 3 months, the
mean change (±s.e.) from baseline was significantly greater
in the intervention group than in the control group (4.5±0.4
vs 2.1±0.6, respectively, Po0.001); after 9 months, the
corresponding figures were 4.4±0.4 and 2.9±0.5, respec-
tively, P¼ 0.031 (Table 2, Figure 3). In the Risk of Suicide
module, there was a significant improvement in the
intervention group after 3 and 9 months when compared
with the baseline values (mean difference: 1.0±0.4 points,
P¼ 0.019; and 1.6±0.5 points, P¼ 0.002, respectively); no
difference was noted in the control group (Table 2).
Secondary outcomes
There was a significant improvement in the intervention
group in several dimensions of the KDQOL-SF after 3 and 9
months, compared with the baseline: burden of renal disease
(mean difference: 14.9±4.3 points, Po0.001 and 14.5±5.3
points, P¼ 0.009, respectively); cognitive function (mean
350 Assessed for eligibility 
12 Refused to answer the protocol
238 Did not meet inclusion criteria
100 Patients with major depression
5 Withdrawn
3 Deaths
1 Hospitalization
1 Excluded
90 Patients were randomized 
46 Started the study in the
intervention (baseline evaluation)
44 Started the study in the control
group (baseline evaluation)
2 Withdrawn
2 Transplanted
1 Excluded
41 Received the intervention (CBT)
and were assessed after 3 months
(evaluation post-intervention)
4 Deaths
1 Transplant
4 Deaths
1 Transplant
1 Withdrawn
36 Were assessed after 9 months
of study (end of follow-up)
38 Were assessed after 9 months
of study (end of follow-up)
44 Were assessed after 3 months
Figure 1 | Flow chart of study participants. CBT, cognitive–
behavioral therapy.
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difference: 12.8±4.1 points, P¼ 0.002 and 16.7±5.0 points,
Po0.001, respectively); quality of social interaction (mean
difference: 15.9±3.9 points, Po0.001 and 16.5±4.7 points,
Po0.001, respectively); sleep (mean difference: 9.5±3.4
points, P¼ 0.006 and 15.0±4.2 points, Po0.001, respec-
tively); overall health (mean difference: 10.7±3.5 points,
P¼ 0.003 and 12.1±4.3 points, P¼ 0.010, respectively); and
mental component summary (mean difference: 9.9±1.8
points, Po0.001 and 8.9±2.3 points, Po0.001, respectively)
(Table 3). No significant difference was observed in the
quality of life scales in the control group. After the
intervention period, compared with the control group, the
CBT group had a significant improvement in the dimensions
of burden of kidney disease, quality of social interaction,
sleep, overall health, and the mental component summary
(Table 3).
There were no changes in the results when all analyses
were repeated adjusting for baseline differences between the
groups in the BDI cognitive subscale, symptom/problem list,
sexual function, dwelling with a family member, and
prevalence of cerebrovascular disease (or excluding from
the analyses, the six patients with cerebrovascular disease in
the control group).
DISCUSSION
In this study, CBT was shown to be effective in the treatment
of depression in patients undergoing hemodialysis. Our
findings show a significant decrease in depression symptoms
and an increase in the quality of life scores in the group
receiving the intervention with CBT for a period of up to 9
months.
Table 1 | Baseline characteristics of the study patients
Characteristics
Intervention
(n=41)
Control
(n=44)
P-
value
Age (years) 52.4±15.9 54.0±12.7 0.610
Gender 0.406
Female 26 (63.4) 24 (54.5)
Male 15 (36.6) 20 (45.5)
Race 0.741
Caucasian 32 (78.1) 33 (75.0)
Non-Caucasian 9 (21.9) 11 (25.0)
Educational level 0.646
Illiterate 9 (22.0) 7 (15.9)
Primary school 25 (61.0) 31 (70.4)
Middle school–High
school/college
7 (17.0) 4 (13.6)
Marital status 0.022
Single 19 (46.3) 10 (22.7)
Married 22 (53.7) 34 (77.3)
Dwelling 0.005
Live with family 34 (82.9) 44 (100.0)
Family monthly income, US$ 680 (350–1050) 875 (382–1192) 0.292
Primary diagnosis 0.784
Diabetes 12 (29.3) 17 (38.6)
Hypertension 14 (34.1) 12 (27.3)
Glomerulonephritis 7 (17.1) 8 (18.2)
Other/unknown 8 (19.5) 7 (15.9)
Congestive heart failure 4 (9.8) 4 (9.1) 1.0
Ischemic heart disease 4 (9.8) 4 (9.1) 1.0
Cerebrovascular disease 0 6 (13.6) 0.026
Peripheral vascular disease 1 (2.4) 2 (4.5) 1.0
Gastrointestinal or
hepatobiliary disease
12 (29.3) 6 (13.6) 0.078
Malignancy 2 (4.9) 2 (4.5) 1.0
Time on dialysis (months) 23.0 (11.5–54.0) 25.5 (12.3–59.8) 0.751
Vascular access 0.659
Arteriovenous fistula 35 (85.4) 36 (81.8)
Venous catheter 6 (14.6) 8 (18.2)
Hospitalization (last month
prior to study start)
7 (17.1) 3 (6.8) 0.186
Waiting list for transplant 19 (46.3) 20 (45.5) 0.935
Previous transplant 2 (4.9) 3 (6.8) 1.0
Antidepressive medication 4 (9.8) 5 (11.4) 1.0
Hemoglobin, g per 100ml 10.9±1.8 10.8±1.8 0.735
Calcium, mg per 100ml 8.8±1.1 9.0±1.0 0.387
Phosphate, mg per 100ml 6.1±1.8 6.3±1.5 0.587
Urea reduction rate, % 66±17 63±10 0.316
Creatinine, mg per 100ml 7.4±3.1 7.2±3.3 0.785
Albumin, g per 100ml 3.8±0.6 3.9±0.7 0.887
Erythropoietin use 31 (76) 32 (73) 0.762
Data are expressed as mean±s.d., n (%) or median (range).
Mean time between laboratory assessment and the beginning of the study
intervention was 17±8 days.
Table 2 |Mean values of the cognitive and somatic subscales,
and overall Beck Depression Inventory (BDI); major depression
and suicide risk modules of the Mini International
Neuropsychiatric Interview (MINI), according to time of study
evaluation and group
Intervention Control P-valuea
BDI Cognitive Subscale
Baseline 13.7±7.1 16.7±7.9 0.069
After 3 months 7.1±5.9 12.1±6.4 o0.001
After 9 months 6.3±7.1 10.8±7.1 0.004
P-valueb o0.001 o0.001
BDI Somatic Subscale
Baseline 10.6±4.0 10.6±4.1 0.929
After 3 months 7.0±3.8 9.1±3.8 0.012
After 9 months 6.1±3.2 9.5±3.9 o0.001
P-valueb o0.001 0.047
BDI total
Baseline 24.2±9.7 27.3±10.7 0.149
After 3 months 14.1±8.7 21.2±9.1 0.001
After 9 months 10.8±8.8 17.6±11.2 0.002
P-valueb o0.001 o0.001
Major Depression Module (MINI)
Baseline 6.4±1.3 6.4±1.2 0.955
After 3 months 1.9±2.8 4.3±2.9 o0.001
After 9 months 2.0±3.1 3.5±2.9 0.006
P-valueb o0.001 o0.001
Suicide Risk Module (MINI)
Baseline 2.2±5.1 1.4±3.5 0.287
After 3 months 1.2±4.2 0.7±1.9 0.433
After 9 months 0.6±1.2 0.6±2.0 0.947
P-valueb 0.007 0.130
Data are expressed as mean±s.d.
aComparison between intervention and control groups.
bOverall comparison within group.
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The prevalence of depression in the studied sample was
28.6%. The prevalence of depression in patients with ESRD is
not definitively established, but it is believed to range
between 20 and 30%.1,20,25 The BDI is the most frequently
used instrument for the assessment of depressive symptoms
in renal patients, and, in comparison with other scales,26,27 it
comprises a wider range of cognitive symptoms. It has been
proposed that a BDI cutoff of 14 is more accurate for the
classification of depression in ESRD patients.28 However, the
best cutoff point may be different depending on the
population and the aims of the study, and a lower cutoff
may be used when a greater sensitivity is desired.29 In this
study, all participants had a total BDI score X10 at study
entry, the mean score was greater than 20 points and the
mean BDI cognitive subscale value was greater than 10 in
both groups, which strongly indicates the presence of
depression.30 Some study participants had mild depressive
symptoms, as a result of including those with a BDI
scorep14. Contrary to other studies, we have not used the
BDI to diagnose depressive disorder. In this case, a low cutoff
point could lead to a false-positive diagnosis. The diagnosis
of depression in this study was confirmed in all patients using
the criteria defined in the MINI. This interview was chosen
because, compared with other diagnostic schedules (the
Composite International Diagnostic Interview31 and the
Structured Clinical Interview for the DSM-III-R32), it has
similar psychometric attributes and is relatively simple and
fast to administer.33
Patients with depression tend to create cognitive distor-
tions, which produce a negative mood status and inadequate
behavior. CBT uses well-structured techniques to promote
the reorganization of negative thoughts, mood status, and
adjustment of behaviors.34 The group receiving CBT in this
study had an improvement of 41.7 and 70.3% in the BDI and
MINI mean scores, respectively, at the end of 3 months of
intervention. The marked decrease in depression symptoms
was probably because of the fact that, during sessions,
patients were encouraged to talk about their thoughts,
instructed to identify and reorganize those thoughts that
might be interfering with their mood status and daily
behaviors, and taught how to create coping strategies to deal
with kidney disease, dialysis treatment, and depression.
Earlier studies showed that patients who had the opportunity
to talk about their feelings and concerns regarding renal
disease, with the help of CBT, had lower depression
scores.35,36 The positive effect in decreasing depression
symptoms in our study was maintained 6 months after the
main intervention period of 3 months, and it is likely that the
monthly reinforcement sessions for the maintenance of the
therapeutic gains obtained with CBT contributed to the
consistency of its effects. It has been recognized that
depressive patients have a higher probability of relapse
within the first year after treatment.37 Taking this into
account, the monthly booster sessions used in the interven-
tion group seem to be a rational way of maintaining the
abilities taught and in preventing relapses.
Several statistical analyses using a longitudinal data
approach through repeated-measures analysis of variance,
and taking into account the baseline parameters that tended
to differ between the groups, confirmed the overall findings.
Therefore, we do not believe that the higher baseline BDI
cognitive scores in the control group (not significantly
different from those in the intervention group) led to biased
results. Moreover, the baseline scores of some KDQOL-SF
dimensions were worse in the intervention group, which
would tend to attenuate the favorable effects observed with
CBT.
It should be noted that, in the CBT treatment group, there
was a significant decrease in the risk of suicide assessed by
MINI, which was not observed in the control group. Suicide
rates in ESRD patients compared with those in the overall US
population are higher by 80%, and many deaths on dialysis
are preceded by treatment discontinuation.38 Depression
symptoms are important predictors of suicide38 and
discontinuation of dialysis.12
Patients from the control group received much less
structured psychological care, but they were provided
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Figure 2 |Meanþ s.e. of the Beck Depression Inventory
(overall BDI score), according to time of study evaluation and
group. P¼ 0.001 for the comparison between groups; Po0.001
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Figure 3 |Meanþ s.e. of the Mini International
Neuropsychiatric Interview (MINI) (Major Depression Module),
according to time of study evaluation and group. Po0.001 for
comparison between groups; Po0.001 for the comparison within
the intervention group; and Po0.001 for the comparison within
the control group.
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emotional support and general guidelines about the treat-
ment. This group also had an improvement over time in the
BDI scales and in the MINI depression module scale, but not
in the KDQOL-SF dimensions. This is not entirely surprising,
as an improvement may occur in some individuals by the
simple participation in a clinical trial; moreover, the control
group also received an active intervention and the observed
improvement may be related to the effect of the brief
individualized supportive psychotherapy.39 However, the
magnitude of this effect was clearly smaller than that in the
CBT group.
A quality of life assessment was also used in this study
because the negative perception of the patients about their
own lives reflects on the results of the treatment and
compromises important areas of their lives.7,8 The group
receiving CBT had a significant improvement in five of the 12
KDQOL-SF dimensions (burden of kidney disease, cognitive
function, quality of social interaction, sleep, and overall
health) and in the SF-36 mental component summary.
As far as we could ascertain, our study is the first in the
literature to show the benefits of group CBT in patients with
chronic kidney disease by means of a randomized controlled
clinical trial. Only three studies were found with regard to
group therapy with CBT for depression in patients with
ESRD.19–21 However, these studies had some important
limitations: one of them only assessed five patients;19 in
another study,20 the author reported his experience using
group and individual CBT in 50 patients, but did not
describe which of the CBT modalities showed better results,
and there was no control group. In the study by Lii et al.,21 a
randomized clinical trial with intervention for 8 weeks, the
sample size was small (n¼ 20), it was not reported whether
the nurses conducting the study had had any specific training
in CBT, the follow-up was short, and little was mentioned
about the treatment given to the control group.
Table 3 |Mean values of the Kidney Disease and Quality of
Life-Short Form (KDQOL-SF) dimensions, according to time
of study evaluation and group
Intervention Control P-valuea
Symptom/problem list
Baseline 65.5±17.1 74.1±13.1 0.014
After 3 months 70.1±19.0 72.6±13.8 0.458
After 9 months 73.0±15.5 70.4±16.4 0.604
P-valueb 0.085 0.519
Effects of kidney disease
Baseline 53.9±16.8 61.3±18.7 0.092
After 3 months 61.5±23.3 59.6±16.5 0.661
After 9 months 61.6±22.6 55.6±22.4 0.372
P-valueb 0.073 0.455
Burden of kidney disease
Baseline 28.7±22.4 22.9±22.8 0.303
After 3 months 43.6±27.1 27.0±27.3 0.004
After 9 months 43.2±28.8 27.3±26.8 0.009
P-valueb 0.002 0.584
Work status
Baseline 11.0±28.5 11.1±27.5 0.960
After 3 months 15.9±32.5 15.7±19.4 0.905
After 9 months 13.9±30.7 14.3±35.1 0.745
P-valueb 0.435 0.454
Cognitive function
Baseline 64.4±23.0 69.1±24.7 0.368
After 3 months 77.2±25.1 71.4±26.3 0.261
After 9 months 81.1±20.5 76.0±23.8 0.334
P-valueb 0.001 0.313
Quality of social interaction
Baseline 65.2±23.3 70.0±22.2 0.345
After 3 months 81.1±19.3 66.5±22.3 0.002
After 9 months 81.7±18.7 71.2±24.4 0.025
P-valueb o0.001 0.485
Sexual function
Baseline 65.8±37.9 90.4±15.6 0.023
After 3 months 75.0±28.0 84.4±23.3 0.418
After 9 months 71.9±25.6 72.5±39.3 0.878
P-valueb 0.730 0.120
Sleep
Baseline 58.1±21.5 58.4±18.7 0.945
After 3 months 67.6±23.0 58.4±17.8 0.034
After 9 months 73.1±19.1 62.8±19.3 0.019
P-valueb 0.001 0.514
Social support
Baseline 74.0±33.3 76.5±27.9 0.670
After 3 months 81.7±25.5 77.7±24.6 0.495
After 9 months 78.7±24.8 77.2±25.2 0.829
P-valueb 0.174 0.951
Dialysis staff encouragement
Baseline 76.8±25.2 80.7±25.1 0.518
After 3 months 79.6±28.6 86.9±21.0 0.218
After 9 months 68.1±33.5 78.9±29.5 0.057
P-valueb 0.027 0.126
Overall health
Baseline 53.2±16.0 56.8±23.0 0.411
After 3 months 63.9±19.3 55.0±19.6 0.046
After 9 months 65.3±19.0 50.0±23.5 0.002
P-valueb o0.001 0.163
Table 3 | Continued
Intervention Control P-valuea
Patient satisfaction
Baseline 66.7±19.7 67.1±19.5 0.933
After 3 months 68.3±22.3 63.3±18.2 0.286
After 9 months 65.7±21.4 62.7±23.4 0.521
P-valueb 0.771 0.485
Physical component summary
Baseline 35.2±9.0 34.7±8.1 0.827
After 3 months 36.2±9.3 33.9±8.0 0.239
After 9 months 37.0±9.6 35.3±8.8 0.391
P-valueb 0.577 0.604
Mental component summary
Baseline 37.4±11.6 41.1±11.2 0.151
After 3 months 47.3±12.1 39.3±11.9 0.002
After 9 months 46.3±12.3 38.6±11.7 0.004
P-valueb o0.001 0.451
Data are expressed as mean±s.d.
aComparison between intervention and control groups.
bOverall comparison within group.
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This study does have some limitations as well: the sample
size was relatively small, only two dialysis centers were
included, and only one practitioner administered the CBT,
which could potentially affect the generalizability of the
results. There were some losses to follow-up, particularly in
the assessment after 9 months (equally distributed between
the groups). Most of these losses were due to death, which is
somewhat expected for ESRD patients after almost 1 year of
follow-up. During the main intervention period, five patients
were not reassessed because of consent withdrawal (n¼ 2),
transplantation (n¼ 2), and exclusion due to psychotic
symptoms (n¼ 1). These losses do not seem to have
influenced the results, as the characteristics of these patients
were similar to those who continued receiving the interven-
tion; furthermore, a similar number of these patients had
mild (n¼ 2), moderate (n¼ 2), and severe (n¼ 1) depression
symptoms. A similar percentage of patients in both groups
used antidepressive medication at study entry and two
additional patients from the control group received anti-
depressants after 6 months of study. It is unlikely that this
factor has influenced our results. A comparison with the
effect of antidepressive medications was not carried out,
because a very small number of patients received them
regularly. Some reports have suggested that CBT is even
superior to the use of antidepressive drugs40,41 and that it can
minimize the rates of discontinuation of antidepressive
medication.42 Finally, as many statistical comparisons were
made, P values close to 0.05 should be interpreted with
caution.
This study presents the advantages of group therapy,
which might be applied in dialysis units to help a large
number of people by means of relatively low costs. Our
findings suggest that CBT is an effective treatment for
depression in patients undergoing hemodialysis. However,
these results must be confirmed by further studies with a
larger number of patients and with different degrees of
severity of depression, so that the results might be general-
ized. In addition, it would be important to evaluate patients
after a longer period of intervention and follow-up.
MATERIALS AND METHODS
A randomized clinical trial was conducted at two dialysis units in the
state of Sa˜o Paulo, Brazil. The study was approved by the
institutional review board, and informed consent was obtained
from all participants. Patients with ESRD receiving outpatient
hemodialysis treatment (average of 4 h per session, 3 times a week)
and between the ages of 18 and 80 years were included. Inclusion
criteria were diagnosis of ESRD on hemodialysis for at least 3
months and diagnosis of a major depressive disorder according to
the MINI43 criteria. Exclusion criteria were having a living-donor
renal transplant scheduled within the next several months, current
hospitalization, psychiatric comorbidity (axis I of the DSM-IV)
diagnosed by the MINI (anxiety disorders (panic disorder,
obsessive-compulsive disorder, posttraumatic stress disorder, gen-
eralized anxiety disorder, social phobia), psychotic syndrome, and
anti-social personality disorder), cognitive impairment (deficiency
of memory or unable to understand the questionnaires) or mental
retardation, current substance abuse, or unstable clinical condition.
Patients with anxiety symptoms, without the above mentioned
diagnoses, were not excluded from the study.
Measures
The MINI43 is a short standardized diagnostic interview (duration
of 15–30 min), compatible with the DSM-IV44 and ICD-10 (ref.45)
criteria. It consists of 19 modules that examine 17 DSM-IV (axis I)
disorders. Psychiatric diagnoses were made according to the clinical
criteria established for each one of the modules. For the diagnosis of
Major Depression, X5 clinical symptoms were required. The
Brazilian version of this questionnaire was validated by Amorim.33
The BDI29 is a 21-item questionnaire that assesses depressive
symptomatology and consists of cognitive (including items about
mood, pessimism, lack of satisfaction, guilty or punishment feelings,
self-dislike, suicidal thoughts, irritability, social withdrawal, and
indecisiveness) and somatic (including items about body image,
work, sleep patterns, fatigue, change in appetite, weight loss, and
loss of interest in sex) subscales. Scores range from 0 to 63, with
higher scores indicating a greater level of depressive symptoms (10
to 16¼mild, 17 to 29¼moderate, and X30¼ severe depressive
symptoms). It was validated in Brazil by Cunha.30
The Kidney Disease and Quality of Life-Short Form (KDQOL-
SF)46 is an instrument used for the assessment of the quality of life
of patients with kidney disease on dialysis. It has 43 disease-specific
items and 36 generic items (SF-36), and consists of 19 dimensions.
The scores for the different items range from 0 to 100, with higher
scores reflecting a better quality of life. This instrument was
validated in Brazil by Duarte et al.47
Patient selection and depression diagnosis
The MINI was administered to all patients undergoing a chronic
hemodialysis program in two dialysis units, who met all inclusion
criteria. Patients with a diagnosis of Major Depression defined by
X5 clinical criteria in the MINI were randomized to the
intervention or the control group.
Randomization
The list for patient allocation was prepared by the research
coordination center following a concealed randomization proce-
dure. A randomization list was prepared according to blocks, and
sealed envelopes were used, containing the patient’s allocation group
according to the following sequence of combinations: AABB/ABAB/
ABBA/BBAA/BABA/BAAB. Randomization was stratified according
to the severity of depression symptoms: separate lists for patients
with mild or moderate symptoms and for those with severe
symptoms. Randomization lists were generated for each participat-
ing center. The envelopes with the treatment code were sealed and
kept at the study site and were consecutively opened when a new
patient was selected for inclusion.
Study procedures
Socio-demographic, clinical, and laboratory data were collected for
all study participants at baseline. The assessment phase with the
administration of the study questionnaires was carried out
immediately before the start of the intervention, after 3 months of
intervention (main intervention period), and at the end of 9 months
of study (including 6 months of maintenance period) in both
groups. The questionnaires were administered and rated by a trained
psychologist who was blinded to the treatment group allocation.
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Intervention
The experimental group received group CBT for 3 months on the
basis of a structured treatment program including 12 weekly
sessions, conducted by a licensed psychologist with extensive
specialized training in CBT (with more than 3700 h of academic
training, including courses, theory, clinical practice for 10 years, and
weekly supervisions). The patients attended sessions when they were
off hemodialysis. The sessions lasted 1 h and 30 min and were
organized on the basis of a manualized methodology proposed by
Lewinsohn et al.48 The first stage of the program consisted of
educating patients on several aspects of renal disease and of dialysis
treatment, an introduction to depression and its symptoms, and an
introduction to the therapeutic cognitive model.34 In the following
steps, the major CBT techniques were introduced and taught: (1)
The self-monitoring of mood status; (2) Cognitive restructuring; (3)
Programming pleasant activities; (4) Training on social abilities and
assertiveness; and (5) Relaxation exercises with positive imagination.
All sessions involved homework as proposed by Greenberg and
Padesky.49 In the third stage, the sessions focused on the closing of
the program and in the prevention of relapses. Eleven intervention
groups were established (average of four participants per group). All
groups were instructed by the same psychologist (co-author, PSD),
who followed an identical procedure. To monitor the fidelity of the
intervention,48 the psychotherapist received regular individual
supervision from another psychologist specialized in CBT, not
directly involved in the research, who checked written records about
the sessions and the activities with the patients throughout the study
period. After the 3-month period of intervention, there was an
additional 6-month period of maintenance phase consisting of
monthly meetings for reinforcement sessions aimed at maintaining
the abilities taught.
Control group
The control group received a brief individualized psychological
consultation, routinely available at the dialysis units. This was
conducted on a weekly basis for 3 months by the unit’s psychologist
during the hemodialysis session. The plan of care was based on a
brief individualized psychotherapy session (mean session duration
of 30–50 min), which consisted of providing general guidelines
about the treatment and emotional support for the patients’
psychological suffering related to the disease and treatment. The
same psychologist (different from the one who conducted the CBT,
with more than 2 years of experience) assisted the patients in the
two participating centers. This psychologist was blinded to the
patients’ allocation and to the study objectives. During the following
6 months, this psychological care was provided whenever necessary
to guarantee the patients’ rights of assistance. No other type of
psychological care was administered to the patients throughout the
study period.
Statistical analyses
Initially, it was estimated that 80 patients (40 per group) would be
required to detect, after the intervention, a reduction X50% in the
BDI scale scores and an increase of 50% in the KDQOL-SF score,
compared with the baseline values. Comparisons between the two
groups for clinical-demographic data were carried out by the w2-test
or Fisher’s exact test for qualitative variables, or by Student’s t-test or
the Mann–Whitney test for quantitative variables. The longitudinal
data approach was used for inferential analysis of the three
assessment time points, with a mixed model using autoregressive
covariance structure.50 Changes in effects between groups with
respect to mean values at each assessment (baseline, 3 and 9
months) and within the same group over time were evaluated with a
repeated-measurement analysis of variance, using a mixed-effect
modeling procedure.51 This analysis takes into account all
measurements at different assessments (baseline, 3 and 9 months)
to determine the predicted mean values at these points. All
comparisons were planned before the analyses, and a P-value
o0.05 was considered to indicate statistical significance. Assump-
tions for the mixed-effects model were tested and satisfied. Analyses
were conducted with the use of SAS software, Cary, NC, USA
(PROC MIXED, version 9.2, SAS Institute).
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